Real-world effectiveness of single agent enfortumab vedotin (EV) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) based on line of therapy and impact of prior platinum (plat) chemotherapy (chemo) and PD-1/PD-L1 inhibitors (PD-1/PD-L1i)

被引：0
作者：
Sayegh, N. [1 ]
Jo, Y. Jung [1 ]
Gebrael, G. [1 ]
Tripathi, N. [1 ]
Chigarira, B. [1 ]
Srivastava, A. [1 ]
Nordblad, B. [1 ]
Dal, E. [1 ]
Chehade, C. Hage [1 ]
Maughan, B. L. [1 ]
Gupta, S. [1 ]
Agarwal, N. [1 ]
Swami, U. [1 ]
机构：
[1] Univ Utah Hlth, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.1029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2380P
引用
收藏
页码：S1212 / S1212
页数：1
相关论文
共 50 条
  • [1] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11) : 1073 - 1074
  • [2] Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma
    Fan, Y.
    Yu, Y.
    Zhai, W.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S702 - S702
  • [3] EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    O'Donnell, P.
    Galsky, M. D.
    Rosenberg, J. E.
    Petrylak, D. P.
    Balar, A. V.
    McGregor, B. A.
    Heath, E.
    Yu, E. Y.
    Quinn, D. I.
    Hahn, N. M.
    Campbell, M.
    Liang, S-Y.
    Steinberg, J.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S579 - S580
  • [4] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
  • [5] EV-201 Cohort 2: Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
    Balar, Arjun Vasant
    McGregor, Bradley Alexander
    Rosenberg, Jonathan E.
    van der Heijden, Michiel Simon
    Park, Se Hoon
    Lee, Jae-Lyun
    Harrison, Michael Roger
    Heath, Elisabeth, I
    Stein, Mark N.
    Loriot, Yohann
    Necchi, Andrea
    Steinberg, Joyce Leta
    Liang Shang-Ying
    Kim, Eric
    Trowbridge, Janet
    Campbell, Mary S.
    Petrylak, Daniel Peter
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [6] Real-world outcomes in locally advanced or metastatic urothelial carcinoma following platinum and PD-1/L1 inhibitor therapy
    Hepp, Zsolt
    Shah, Sonali N.
    Liang, Shang-Ying
    Tan, Katherine
    Balakrishna, Shreya
    FUTURE ONCOLOGY, 2021, 17 (32) : 4343 - 4353
  • [7] Real-world efficacy of PD-1/PD-L1 inhibitors in patients with advanced pulmonary neuroendocrine carcinoma: a single-center analysis
    Zhai, Wanchen
    Yu, Ying
    Wu, Haicheng
    Zhang, Qian
    Chen, Yunfei
    Yang, Yehao
    Fan, Yun
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [8] Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.
    McGregor, Bradley Alexander
    Balar, Arjun Vasant
    Rosenberg, Jonathan E.
    Van der Heijden, Michiel Simon
    Park, Se Hoon
    Lee, Jae-Lyun
    Kojima, Takahiro
    Harrison, Michael Roger
    Heath, Elisabeth I.
    Stein, Mark N.
    Loriot, Yohann
    Necchi, Andrea
    Steinberg, Joyce Leta
    Liang, Shang-Ying
    Trowbridge, Janet
    Petrylak, Daniel P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Activity of single-agent PD-1/PD-L1 inhibitors in 1st-line (1L) "platinum-ineligible" patients (pts) with metastatic urothelial cancer (mUC) in real-life clinical practice
    Molina Cerrillo, J.
    Ortego, I.
    Pinto Marin, A.
    Alonso Gordoa, T.
    Puente, J.
    Arranz Arija, J. A.
    Lopez Criado, M. P.
    Gonzalez Morales, A.
    Vidal Cassinello, N.
    Castellano Gauna, D. E.
    Sevillano Fernandez, E.
    Garcia Donas, J.
    Grande Pulido, E.
    ANNALS OF ONCOLOGY, 2022, 33 : S1490 - S1490
  • [10] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
12345